InvestorsHub Logo
Followers 27
Posts 1204
Boards Moderated 0
Alias Born 09/11/2010

Re: None

Thursday, 11/03/2011 7:27:21 AM

Thursday, November 03, 2011 7:27:21 AM

Post# of 97237
Sheff Can I ask your thoughts on ZGNX thanks

ZGNX not sure if anyone here following Insiders own a ton of stock & bought another 7 million shares on last offering at $2.00. Has a positive phase 3 trial completed & will apply for FDA approval in 2012 with a 2013 launch. Their target Mkt is the largest in the U.S 131 Million scripts written for Hydrocodone.Been churning in base here at $2 for last 6 weeks & looking slightly better lately From CEO

Roger Hawley, Chief Executive Officer of Zogenix, said, "These positive results represent an important step forward in the commercialization of our extended-release hydrocodone. Adding Zohydro as our second commercial product would be transformational for Zogenix's business, given the number of chronic pain patients and the growing physician demand for an acetaminophen-free hydrocodone product. If approved, as planned, we intend to expand our sales force in order to be in a position to educate prescribers about this important new option for chronic pain management and assume a greater promotional responsibility for SUMAVEL DosePro."

"Stephen J. Farr, Ph.D., President and Chief Operating Officer of Zogenix, "We are very encouraged by the study results, which we believe are meaningful for patients suffering from moderate to severe chronic pain. Zohydro will offer hydrocodone for the first time in a convenient 12-hour dose while eliminating acetaminophen. Zohydro may simplify physicians' ability to prescribe the appropriate hydrocodone dose for chronic pain while managing the inadvertent overuse of acetaminophen, which is a common ingredient in combination pain products and over-the-counter medications."

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.